Literature DB >> 16955398

Chemokine receptor expression profiles in nasopharyngeal carcinoma and their association with metastasis and radiotherapy.

D-L Ou1, C-L Chen, S-B Lin, C-H Hsu, L-I Lin.   

Abstract

Nasopharyngeal carcinoma (NPC) is an epithelial cancer that metastasizes predictably to cervical lymph nodes or distant organs. To assess whether the chemokine receptors of NPC cells play important roles in metastasis and are associated with radiotherapy history, the significance of various chemokine receptors (CCR1-10, CXCR1-6, XCR1, and CX3CR1) in NPC cell lines (TW01, TW04, HONE1, BM1, and AS1) and 52 NPC tumour biopsies from 48 patients with NPC was evaluated by mRNA and cytometric analyses, chemotaxis and actin polymerization assays, and immunohistochemical staining. Quantitative real-time reverse transcription-polymerase chain reaction revealed substantial expression of CCR7, CCR9, CXCR4, and CXCR6 mRNA in all the NPC cell lines. Of these, however, only CCR7, CXCR4, and CXCR6 were functional in NPC cells. Negative immunoreactivity for CCR7, CXCR4, and CXCR6 was demonstrated in almost all nasopharyngeal (NP) specimens from patients with primary NPC (n = 12) and in those with regional metastatic NPC (n = 15). However, expression of two or three of these chemokine receptors was demonstrated in NP specimens from patients with liver metastasis. Strong positivity was demonstrated for all three of these chemokine receptors in almost all of the regional and distant metastasis specimens. Significant differences in the expression of CCR7, CXCR4, and CXCR6 were found between primary tumours and metastases (p < 0.001, p < 0.001, and p < 0.002, respectively). This observation was further confirmed by laser capture microdissection of freshly frozen tumours from primary (n = 5) and metastatic (n = 8) NPC sites (p = 0.04, 0.03, and 0.03 for CCR7, CXCR4, and CXCR6, respectively). Finally, significant differences in CXCR4 expression were demonstrated between de novo and post-radiotherapy groups (1/22 vs. 5/8; p < 0.003). It appears reasonable to conclude, therefore, that CCR7, CXCR4, and CXCR6 are expressed and active in human NPC metastases, while CXCR4 expression is associated with radiotherapy history. Copyright 2006 Pathological Society of Great Britain and Ireland.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16955398     DOI: 10.1002/path.2053

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  28 in total

1.  CXCR4 inhibition enhances radiosensitivity, while inducing cancer cell mobilization in a prostate cancer mouse model.

Authors:  Urszula M Domanska; Jennifer C Boer; Hetty Timmer-Bosscha; Marcel A T M van Vugt; Hilde D Hoving; Nathalie M Kliphuis; Stefano Rosati; Henk G van der Poel; Igle Jan de Jong; Elisabeth G E de Vries; Annemiek M E Walenkamp
Journal:  Clin Exp Metastasis       Date:  2014-08-26       Impact factor: 5.150

2.  Prostate cancer cells hyper-activate CXCR6 signaling by cleaving CXCL16 to overcome effect of docetaxel.

Authors:  Neeraj Kapur; Hina Mir; Guru P Sonpavde; Sanjay Jain; Sejong Bae; James W Lillard; Shailesh Singh
Journal:  Cancer Lett       Date:  2019-04-08       Impact factor: 8.679

3.  Inflammatory CXCL12-CXCR4/CXCR7 axis mediates G-protein signaling pathway to influence the invasion and migration of nasopharyngeal carcinoma cells.

Authors:  Naian Qiao; Lin Wang; Tao Wang; Haiying Li
Journal:  Tumour Biol       Date:  2015-12-29

4.  MiR-139 targets CXCR4 and inhibits the proliferation and metastasis of laryngeal squamous carcinoma cells.

Authors:  Hua-Nan Luo; Zheng-Hui Wang; Ying Sheng; Qing Zhang; Jing Yan; Jin Hou; Kang Zhu; Ying Cheng; Ying-Long Xu; Xiang-Hong Zhang; Min Xu; Xiao-Yong Ren
Journal:  Med Oncol       Date:  2013-12-07       Impact factor: 3.064

Review 5.  C-C Chemokine Receptor 7 in Cancer.

Authors:  Colin A Bill; Christopher M Allen; Charlotte M Vines
Journal:  Cells       Date:  2022-02-14       Impact factor: 6.600

6.  Expression analysis and clinical significance of CXCL16/CXCR6 in patients with bladder cancer.

Authors:  Jun Taik Lee; Sang Don Lee; Jeong Zoo Lee; Moon Kee Chung; Hong Koo Ha
Journal:  Oncol Lett       Date:  2012-10-17       Impact factor: 2.967

7.  Expression of chemokine receptor CXCR4 is closely correlated with clinical outcome in human nasopharyngeal carcinoma.

Authors:  Hengmin Tao; Yumei Wei; Congan Wang; Kun Yang; Wei Huang; Haitao Liu; Baosheng Li
Journal:  Tumour Biol       Date:  2015-11-26

Review 8.  G-protein coupled chemoattractant receptors and cancer.

Authors:  Jian Huang; Keqiang Chen; Wanghua Gong; Nancy M Dunlop; Ji Ming Wang
Journal:  Front Biosci       Date:  2008-05-01

9.  The chemokine CXCL16 and its receptor, CXCR6, as markers and promoters of inflammation-associated cancers.

Authors:  Merav Darash-Yahana; John W Gillespie; Stephen M Hewitt; Yun-Yun K Chen; Shin Maeda; Ilan Stein; Satya P Singh; Roble B Bedolla; Amnon Peled; Dean A Troyer; Eli Pikarsky; Michael Karin; Joshua M Farber
Journal:  PLoS One       Date:  2009-08-19       Impact factor: 3.240

10.  CXCR6 induces prostate cancer progression by the AKT/mammalian target of rapamycin signaling pathway.

Authors:  Jianhua Wang; Yi Lu; Jingchen Wang; Alisa E Koch; Jian Zhang; Russell S Taichman
Journal:  Cancer Res       Date:  2008-12-15       Impact factor: 13.312

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.